Tim Friede's Venom Immunity Sparks New Antivenom Research
Groundbreaking research into snakebite treatment using unique antibodies from Tim Friede reveals potential for broad-spectrum antivenom.
Subscribe to unlock this story
We really don't like cutting you off, but you've reached your monthly limit. At just $5/month, subscriptions are how we keep this project going. Start your free 7-day trial today!
Get StartedHave an account? Sign in
Overview
After 18 years of self-immunization with venom, Tim Friede's antibodies have led researchers at Centivax to design a groundbreaking broad-spectrum antivenom. Studying Friede's blood, scientists identified two antibodies effective against venom from multiple snake species. Their experimental formula showed promise in mice, offering protection against 13 species and partial against others, but has yet to enter human trials. Despite its potential, experts caution more work is needed, particularly for snakes like vipers. Friede's unique journey, involving hundreds of snakebites, highlights a significant advancement in snakebite treatment amidst a global health crisis.
Report issue
Read both sides in 5 minutes each day
Analysis
- A new universal antivenom for snake bites has been developed using human antibodies from Tim Friede, who self-immunized with snake venom over 18 years. This research is viewed as a major breakthrough in snake bite treatment.
- The current antivenom methods rely on animal-derived antibodies which can cause severe allergic reactions; the new development aims to eliminate these risks and improve accessibility and effectiveness in treating snakebites globally.
- Field trials on dogs are planned, with hopes to transition to human trials, highlighting the urgency of addressing the global health crisis posed by snake bites, particularly in underserved areas.
Articles (6)
FAQ
The antivenom provided complete protection against venom from 13 snake species and partial protection against 6 additional species in mouse studies.
The two critical antibodies identified are LNX-D09 and X-B03.
The current antivenom focuses on elapids (e.g., mambas, cobras) and has not been tested or optimized for viperid snakes, which require separate antibody development.
Varespladib, a toxin-blocking drug, was combined with the antibodies to extend protection against additional snake species.
Researchers must complete clinical trials in humans and refine the antibody cocktail, with veterinary trials in dogs underway as an intermediate step.
History
- 4M
3 articles